Oxidative Lipidomics in Pediatric Traumatic Brain Injury
氧化脂质组学在小儿创伤性脑损伤中的应用
基本信息
- 批准号:10844023
- 负责人:
- 金额:$ 33.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcyltransferaseAdultAffinityAnti-Inflammatory AgentsAntioxidantsApoptoticArachidonate 15-LipoxygenaseArachidonic AcidsBiochemical ReactionBrainBrain InjuriesCardiolipinsCause of DeathCessation of lifeChildChildhood InjuryChronicClinical TrialsCoenzyme A LigasesCollaborationsComplexDataEndoplasmic ReticulumEnzymesEsterificationEventFamily memberFree Radical ScavengersFree RadicalsFundingGenerationsGlutathioneHospitalizationHydrogen PeroxideHydrolysisHydroxidesImageInduction of ApoptosisInflammatory ResponseInjuryInnovative TherapyIronLinkLipid PeroxidationLipoxygenase InhibitorsLysophosphatidylcholinesMechanicsMembraneMitochondriaMorbidity - disease rateNational Center for Advancing Translational SciencesNatureNeurological outcomeNeuronsOxidation-ReductionOxidative StressPathogenicityPathway interactionsPatternPeroxidasesPhosphatidylethanolaminePhosphatidylethanolamine Binding ProteinPhospholipasePhospholipidsProteinsRattusReduced GlutathioneRoleScaffolding ProteinSignal TransductionSourceStretchingSubstrate SpecificitySulfhydryl CompoundsSystemTBI treatmentTechnologyTestingTherapeuticTherapeutic UsesTranslationsTraumaTraumatic Brain InjuryUnited States National Institutes of HealthWorkadductbaicaleincatalystcognitive functioncontrolled cortical impactcytochrome cdesigndrug discoveryexperimental studyglutathione peroxidaseimproved outcomeinhibitorlipidomicsliquid chromatography mass spectrometrymortalityneuron apoptosisneuron lossneuroprotectionnew therapeutic targetnovel therapeuticsoxidationpediatric traumatic brain injuryperoxidationpostnatalpreferencepreservationpreventprotein complexsmall moleculesmall molecule inhibitorstandard caretargeted treatment
项目摘要
Each year in the US, severe TBI in children results in ∼7400 deaths and 60 000 hospitalizations. Fifty percent
of surviving children with severe TBI have poor neurological outcome at six months. Severe TBI in children is
thus a critical problem in desperate need of impactful therapies. Free radicals and oxidative stress have been
uniformly accepted as universal pathogenic mechanisms of TBI prompting therapeutic use of antioxidants.
Invariably, clinical trials of non-specific free radical scavengers/antioxidants failed. This suggests that true
sources and mechanisms of TBI redox disbalance remain undefined, and represent a potential therapeutic
opportunity. During the previous funding period we showed that lipid peroxidation after TBI in immature brain
occurs as a result of controlled enzymatic reactions. We discovered that peroxidation of mitochondrial
phospholipid cardiolipin (CL) represents a required stage of neuronal apoptosis after TBI in postnatal day
(PND) 17 rats. We identified cytochrome c as a catalyst of CL peroxidation and showed that a mitochondria-
targeted inhibitor of CL peroxidation suppressed TBI-induced apoptosis and preserved cognitive function in
PND17 rats. Our latest work identified highly selective oxidation of arachidonic acid (AA) containing
phosphatidylethanolamines (PE) by 15 lipoxygenase (15LOX) to be causative to ferroptosis. We discovered
that PE binding protein 1 (PEBP1) complexes with 15LOX and changes its substrate specificity from free AA to
AA esterified into PE to generate hydroperoxy-AA-PE death signals. Normally hydroperoxy-AA-PE are
eliminated by combined action of glutathione peroxidase 4 (GPX4)/glutathione (GSH). Immature brain has
lower GSH levels and GPX activity vs adult brain thus could be more vulnerable to ferroptosis upon injury.
Indeed our preliminary data show that TBI leads to marked increase in expression and activity of 15LOX, and
accumulation of oxidized AA-PE in PND17 rat brain. Furthermore, preliminary data indicate that inhibition of
AA-PE oxidation suppresses TBI-induced neuronal death and preserves cognitive function. Thus, we
hypothesize that generation of oxidized AA-PE by 15LOX/PEBP1 complex leads to neuronal death and
represents a new target for drug discovery leading to innovative therapies in pediatric TBI. We propose to test
our hypothesis in three Specific Aims. Aim 1 will determine the degree, spatial and temporal pattern of
15LOX/PEBP1 complex formation and AA-PE oxidation after TBI. Aim 2 will investigate the mechanisms of
AA-PE oxidation in TBI-induced neuronal death. Aim 3 will design and investigate the mechanism of action and
neuroprotective potential of small-molecule regulators of 15LOX and 15LOX/PEBP1 activity in TBI. These
studies will employ powerful lipidomics and oxidative lipidomics technology to provide important mechanistic
information on the role of PE oxidation in neuronal ferroptosis after pediatric TBI. The ability to selectively
modulate PE oxidation, a critical early event in the mechanism of ferroptosis, could lead to targeted therapies
for TBI and ultimately improve outcome for children after brain injury.
在美国,严重的 TBI 每年导致约 7400 人死亡,60 000 人住院治疗。
患有严重 TBI 的幸存儿童在六个月时神经功能状况不佳。
因此,自由基和氧化应激是迫切需要有效治疗的一个关键问题。
普遍认为 TBI 的普遍致病机制促使抗氧化剂的治疗使用。
非特异性自由基清除剂/抗氧化剂的临床试验总是失败,这表明这是正确的。
TBI 氧化还原失衡的来源和机制仍不清楚,但代表了一种潜在的治疗方法
在之前的资助期间,我们发现未成熟大脑中 TBI 后的脂质过氧化。
我们发现线粒体的过氧化反应是受控酶反应的结果。
磷脂心磷脂 (CL) 代表出生后 TBI 后神经元凋亡的必要阶段
(PND) 17 只大鼠,我们鉴定出细胞色素 c 是 CL 过氧化的催化剂,并表明线粒体-
CL过氧化的靶向抑制剂抑制了TBI诱导的细胞凋亡并保留了认知功能
我们最新的工作鉴定了 PND17 大鼠中含有的花生四烯酸 (AA) 的高度选择性氧化。
我们发现 15 脂氧合酶 (15LOX) 产生的磷脂酰乙醇胺 (PE) 会导致铁死亡。
PE 结合蛋白 1 (PEBP1) 与 15LOX 复合,并将其底物特异性从游离 AA 改变为
AA酯化到PE中产生氢过氧-AA-PE死亡信号通常氢过氧-AA-PE是。
通过谷胱甘肽过氧化物酶 4 (GPX4)/谷胱甘肽 (GSH) 的联合作用消除 未成熟的大脑。
与成人大脑相比,GSH 水平和 GPX 活性较低,因此在受伤时更容易出现铁死亡。
事实上,我们的初步数据表明,TBI 导致 15LOX 的表达和活性显着增加,并且
PND17 大鼠脑中氧化 AA-PE 的积累此外,初步数据表明,抑制
AA-PE 氧化可抑制 TBI 诱导的神经元死亡并保留认知功能。
促进了 15LOX/PEBP1 复合物生成氧化 AA-PE 导致神经元死亡
代表了药物发现的新目标,导致儿童 TBI 的创新疗法。我们建议进行测试。
我们在三个具体目标 1 中的假设将决定的程度、空间和时间模式。
目标 2 将研究 TBI 后 15LOX/PEBP1 复合物的形成和 AA-PE 氧化的机制。
AA-PE 氧化在 TBI 诱导的神经元死亡中的作用 目标 3 将设计和研究其作用机制。
15LOX 和 15LOX/PEBP1 活性的小分子调节剂在 TBI 中的神经保护潜力。
研究将采用强大的脂质组学和氧化脂质组学技术来提供重要的机制
关于 PE 氧化在儿科 TBI 后神经元铁死亡中的作用的信息
调节 PE 氧化(铁死亡机制中的一个关键早期事件)可能会导致靶向治疗
治疗 TBI 并最终改善脑损伤后儿童的预后。
项目成果
期刊论文数量(37)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Successive High-Resolution (H2O)n-GCIB and C60-SIMS Imaging Integrates Multi-Omics in Different Cell Types in Breast Cancer Tissue.
连续高分辨率 (H2O)n-GCIB 和 C60-SIMS 成像集成了乳腺癌组织中不同细胞类型的多组学。
- DOI:
- 发表时间:2021-06-15
- 期刊:
- 影响因子:7.4
- 作者:Tian, Hua;Sparvero, Louis J;Anthonymuthu, Tamil Selvan;Sun, Wan;Amoscato, Andrew A;He, Rong;Bayır, Hülya;Kagan, Valerian E;Winograd, Nicholas
- 通讯作者:Winograd, Nicholas
Integrated -omics approach reveals persistent DNA damage rewires lipid metabolism and histone hyperacetylation via MYS-1/Tip60.
综合组学方法揭示了持续性 DNA 损伤通过 MYS-1/Tip60 重新连接脂质代谢和组蛋白过度乙酰化。
- DOI:
- 发表时间:2022-02-18
- 期刊:
- 影响因子:13.6
- 作者:Hamsanathan, Shruthi;Anthonymuthu, Tamil;Han, Suhao;Shinglot, Himaly;Siefken, Ella;Sims, Austin;Sen, Payel;Pepper, Hannah L;Snyder, Nathaniel W;Bayir, Hulya;Kagan, Valerian;Gurkar, Aditi U
- 通讯作者:Gurkar, Aditi U
Cardiolipin-Dependent Mitophagy Guides Outcome after Traumatic Brain Injury.
心磷脂依赖性线粒体自噬指导创伤性脑损伤后的结果。
- DOI:
- 发表时间:2019-03-06
- 期刊:
- 影响因子:0
- 作者:Chao, Honglu;Lin, Chao;Zuo, Qiang;Liu, Yinlong;Xiao, Mengqing;Xu, Xiupeng;Li, Zheng;Bao, Zhongyuan;Chen, Huimei;You, Yongping;Kochanek, Patrick M;Yin, Huiyong;Liu, Ning;Kagan, Valerian E;Bayır, Hülya;Ji, Jing
- 通讯作者:Ji, Jing
Mitochondrial damage & lipid signaling in traumatic brain injury.
线粒体损伤
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:5.3
- 作者:Lamade, Andrew M;Anthonymuthu, Tamil S;Hier, Zachary E;Gao, Yuan;Kagan, Valerian E;Bayır, Hülya
- 通讯作者:Bayır, Hülya
Elimination of the unnecessary: Intra- and extracellular signaling by anionic phospholipids.
消除不必要的:阴离子磷脂的细胞内和细胞外信号传导。
- DOI:
- 发表时间:2017-01-15
- 期刊:
- 影响因子:3.1
- 作者:Kagan, Valerian E;Bayır, Hülya;Tyurina, Yulia Y;Bolevich, Sergey B;Maguire, John J;Fadeel, Bengt;Balasubramanian, Krishnakumar
- 通讯作者:Balasubramanian, Krishnakumar
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hülya Bayir其他文献
Hülya Bayir的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hülya Bayir', 18)}}的其他基金
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡的调节性坏死途径的辐射缓解剂
- 批准号:
10838232 - 财政年份:2023
- 资助金额:
$ 33.61万 - 项目类别:
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡调节坏死途径的辐射缓解剂
- 批准号:
10625932 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Druggable Mitochondrial Targets for Treatment of Cerebral Ischemia
用于治疗脑缺血的可药物线粒体靶点
- 批准号:
10592289 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡调节坏死途径的辐射缓解剂
- 批准号:
10212243 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Druggable Mitochondrial Targets for Treatment of Cerebral Ischemia
用于治疗脑缺血的可药物线粒体靶点
- 批准号:
10328870 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡调节坏死途径的辐射缓解剂
- 批准号:
10436895 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Druggable Mitochondrial Targets for Treatment of Cerebral Ischemia
用于治疗脑缺血的可药物线粒体靶点
- 批准号:
10090670 - 财政年份:2020
- 资助金额:
$ 33.61万 - 项目类别:
Mitochondria-Targeted Redox Therapy for Cerebral Ischemia in the Developing Brain
线粒体靶向氧化还原疗法治疗发育中大脑缺血
- 批准号:
8733232 - 财政年份:2014
- 资助金额:
$ 33.61万 - 项目类别:
Mitochondria-Targeted Redox Therapy for Cerebral Ischemia in the Developing Brain
线粒体靶向氧化还原疗法治疗发育中大脑缺血
- 批准号:
8994750 - 财政年份:2014
- 资助金额:
$ 33.61万 - 项目类别:
Mitochondria-Targeted Redox Therapy for Cerebral Ischemia in the Developing Brain
线粒体靶向氧化还原疗法治疗发育中大脑缺血
- 批准号:
8820302 - 财政年份:2014
- 资助金额:
$ 33.61万 - 项目类别:
相似国自然基金
两种溶血磷脂酸酰基转移酶参与大豆花叶病毒复制与宿主抗性的机制研究
- 批准号:32370158
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
灵芝中灵芝酸生物合成关键酰基转移酶的鉴定和功能研究
- 批准号:32360014
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
酰基转移酶选择性催化酯化虾青素合成的分子机制研究
- 批准号:32372283
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于串级质谱的磷脂酰胆碱酰基转移酶对底物异构体的选择性研究
- 批准号:22304088
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
二酰基甘油O-酰基转移酶1调控自噬流影响前列腺癌生长的作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
假单胞菌脂质 A 结构在 CF 气道疾病进展中的微生物适应
- 批准号:
10722599 - 财政年份:2023
- 资助金额:
$ 33.61万 - 项目类别:
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
奥利司他治疗 1 型高脂蛋白血症的长期疗效和安全性:一项随机、双盲、安慰剂对照试验
- 批准号:
10570530 - 财政年份:2023
- 资助金额:
$ 33.61万 - 项目类别:
Role and Function of Peroxisomal Ether Phospholipids in TBI
过氧化物酶体醚磷脂在 TBI 中的作用和功能
- 批准号:
10218660 - 财政年份:2021
- 资助金额:
$ 33.61万 - 项目类别:
Hepatoprotective Mechanisms of TTC39B Deficiency
TTC39B 缺陷的保肝机制
- 批准号:
10407976 - 财政年份:2018
- 资助金额:
$ 33.61万 - 项目类别:
Hepatoprotective Mechanisms of TTC39B Deficiency
TTC39B 缺陷的保肝机制
- 批准号:
10153765 - 财政年份:2018
- 资助金额:
$ 33.61万 - 项目类别: